Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.
The assistant professor at Hunter College talked about how to effectively diagnose and treat multiple sclerosis through localization and active listening of the patient's history and symptoms. [WATCH TIME: 7 minutes]
The associate vice president of research at National MS Society talked about proactive and early referral to rehabilitation services to effectively manage multiple sclerosis symptoms from the outset. [WATCH TIME: 4 minutes]
The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals provided clinical insight on a new study evaluating the effect of switching from high- to low-sodium oxybate on blood pressure. [WATCH TIME: 4 minutes]
In the final episode, Negroski gave closing thoughts on some of the major unmet needs in research regarding aging in MS, as well as some of the unanswered questions clinicians are still trying to figure out.
Donald Negroski, MD, gave an overview of a study that highlighted an accelerated biologic aging clock among patients with pediatric-onset MS.
The associate professor of neurology at Georgetown University Medical Center talked about innovative treatments for dementia in movement disorders that target multiple mechanisms to effectively modify the disease. [WATCH TIME: 7 minutes]
The executive director of the Association of Movement Disorder Advanced Practice Providers talked about a recent survey highlighting why patients with movement disorders may withhold critical health information from their providers.
The associate professor of neurology at Georgetown University Medical Center talked about the potential of tyrosine kinase inhibitors in treating neurodegenerative diseases. [WATCH TIME: 7 minutes]
The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]
The nurse practitioner at the Cleveland Clinic talked about findings from a recent study focused on enhancing medication management and education for patients with Parkinson disease. [WATCH TIME: 5 minutes]
The movement disorder specialist at Texas Movement Disorder Specialists talked about the complexities and advancements in treating Parkinson disease, emphasizing the need for strategic and aggressive treatment approaches despite administrative burdens. [WATCH TIME: 5 minutes]
The assistant clinical professor of medicine at Medstar Georgetown University Hospital highlighted the need for clinicians to maintain informed, open-minded discussions about therapeutic options. [WATCH TIME: 2 minutes]
Negroski detailed a real-world analysis on cladribine, an FDA-approved DMT, in an aging population of MS, and the recent increase in research for older populations with the disease.
In this episode, Negroski gave insight on the impact of health care-related social determinants of health, their impact on brain structure and aging in MS, and where efforts should be directed towards going forward.
The associate professor of neurology at Mayo Clinic College of Medicine discussed findings from a post-hoc analysis of the phase 3 PREVAIL study presented at AHS 2024 assessing eptinezumab in patients with chronic migraine. [WATCH TIME: 4 minutes]
The professor and chair of neurology at New York Medical College discussed her extensive involvement in neurology education and the recent efforts to enhance neurology education through various programs. [WATCH TIME: 5 minutes]
The Cleveland Clinic Foundation Parkinson's Inpatient Program is a proactive, multidisciplinary intervention aimed to enhance the quality and safety of care for hospitalized patients with Parkinson disease.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Anne Marie Morse, DO, FAAN. [LISTEN TIME: 18 minutes]
In this segment, Negroski comments on the realism behind wearing off effect of treatments, specifically ocrelizumab, and how clinicians may work around some of these issues.
Additional data of a phase 2 study presented at the 2024 SLEEP Annual Meeting demonstrated that pitolisant significantly improved in secondary end points among patients with myotonic dystrophy type 1.
Negroski discussed some of the takeaways from an analysis of patients with stable MS who chose to switch from natalizumab to other, more moderate-efficacy oral disease-modifying therapies.
Istradefylline led to significant reductions in tremor and motor symptoms in patients with Parkinson disease over 24 weeks.
Findings revealed that 27% of patients responded to the treatment of continuous subcutaneous apomorphine infusion and sustained efficacy overtime in patients with Parkinson disease.
The movement disorder specialist at Texas Movement Disorder Specialists talked about a comprehensive panel discussion that highlighted the evolution of Parkinson disease treatment. [WATCH TIME: 4 minutes]
The nurse practitioner at the Cleveland Clinic talked about a specialized program involving nurse practitioners that aims to improve inpatient care quality and safety for patients with Parkinson disease. [WATCH TIME: 5 minutes]
The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a phase 3 trial assessing a pharmaceutical treatment, AD109, in sleep apnea.
Bezisterim has shown potential in improving non-motor symptoms like fatigue and sleep issues, with promising results from previous studies.
Modified Functional Status Questionnaire, an assessment of activities of daily living, includes several different notable domains, including quality of interaction, social activity, and psychological function.
The director of the Memory Disorders Program at Georgetown University talked about newly approved anti-amyloid antibodies that show significant promise in slowing Alzheimer disease progression. [WATCH TIME: 5 minutes]
